Clinical Trial Update: IRESSA™ (Gefitinib) in Breast Cancer Patients [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 trial of gefitinib (IRESSA) in breast cancer patients that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED